Novo

Seniors in Medicare will gain landmark obesity drug coverage starting July 1, but many may remain unaware due to limited government and company advertising.

An Ebola outbreak in Congo has led to a 40% increase in cases within a week, with confirmed deaths exceeding 200. The U.S. CDC has activated $107 million in funds, and hackers are demanding $75 million from Novo. An ACIP investigation has been launched regarding the outbreak.

Denmark is studying whether Wegovy can increase employment rates. The country was among the first to launch the drug in late 2022.

Novo CEO states that there are no plans to lower Wegovy prices further. This decision may impact the accessibility of the medication. The statement provides clarity on the company's pricing strategy.

Novo raises its forecast due to strong sales of its Wegovy pill. The company's revenue is expected to increase as a result. This growth is driven by the popularity of the Wegovy medication.

Hemab, a biotech company backed by Novo, raised $301.5 million in an upsized IPO. The funding will support its focus on blood-related clinical research and development.

Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range. The stock surged 44% on its first day of trading, with CEO Lyn Baranowski ringing the opening bell at Nasdaq MarketSite in New York.

Avalyn, a drugmaker backed by Novo, raised $300 million in an upsized IPO. Its drug AP01 has completed a clinical trial for idiopathic pulmonary fibrosis.

Hemab, a biotech company backed by Novo, is seeking to raise $212 million through a US IPO. The company is focused on medical research and development.